Welcome to our dedicated page for FMC SEC filings (Ticker: FMC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
FMC Corporation filings document the regulatory record of a NYSE-listed agricultural sciences company with common stock trading under FMC. Recent 8-K reports disclose operating results, material credit-agreement amendments, financial covenants, subsidiary guarantees, collateral arrangements, dividend limitations, restructuring charges, and governance changes.
Proxy materials describe annual meeting matters, stockholder voting procedures, and equity incentive plan approvals. Together, the filings cover FMC's capital structure, board oversight, compensation programs, manufacturing footprint actions, risk-related covenant terms, and recurring financial reporting for its crop protection business.
State Street Corporation reported beneficial ownership of 6,508,613 shares of FMC Corp common stock, representing 5.2% of the class as of June 30, 2026. These shares are held with no sole voting or dispositive power, but with 6,138,301 shares under shared voting power and 6,508,613 shares under shared dispositive power.
The position is held through various State Street asset management and trust subsidiaries, including SSGA Funds Management, Inc. and State Street Bank and Trust Company, among others. No other person is identified as having a more-than-5% economic interest through rights to dividends or sale proceeds.
For the quarter ended June 30, 2026, FMC Corporation reported revenue of $867.1 million, down from $1,050.5 million a year earlier, and a net loss attributable to stockholders of $186.6 million versus prior net income of $66.7 million. Diluted EPS was $(1.49), including $222.3 million of restructuring and other charges tied to Project Foundation, manufacturing exits, the India business held for sale and environmental items.
For the first half of 2026, FMC generated revenue of $1,625.7 million and a net loss of $467.9 million, with $299.3 million of restructuring and other charges and an additional $123 million valuation allowance on Swiss deferred tax assets. Operating cash flow from continuing operations was $(237.9 million). The company issued $1.2 billion of 8.0% Senior Secured Notes due 2031, received a $200.0 million prepurchase payment under a rimisoxafen license with Corteva, and ended June 30, 2026 with $476.6 million of cash and $4,280.6 million of total debt.
FMC Corporation reported second quarter 2026 revenue of $867.1 million, down 17% versus Q2 2025, with revenue excluding India down 20% and organic revenue down 22%. The company posted a GAAP net loss attributable to stockholders of $186.6 million, or $(1.49) per diluted share, versus earnings of $0.53 a year earlier. Adjusted EBITDA was $152.6 million, down 26%, and adjusted EPS was $0.26, down 62%.
Operating cash flow improved sharply to $363.0 million, driving free cash flow of $357.4 million versus $39.7 million in Q2 2025, aided by a $200 million rimisoxafen licensing payment. FMC outlined actions expected to generate approximately $1 billion of proceeds for debt reduction, including a $252 million India commercial business sale, $200 million rimisoxafen license, $114 million Newark sale-leaseback, and a $400 million equity investment from Tessenderlo Group. Full-year 2026 guidance was lowered: revenue excluding India is now $3.50–$3.70 billion, adjusted EBITDA $620–$680 million, and adjusted EPS $1.19–$1.49, all down materially versus 2025, with a return to year-over-year growth expected in Q4.
BlackRock, Inc. reports beneficial ownership of common stock of FMC Corporation on a Schedule 13G/A (Amendment No. 20) as of June 30, 2026. BlackRock and its reporting business units beneficially own 19,345,361 FMC common shares, representing 15.5% of the class.
BlackRock has sole voting power over 19,137,958 shares and sole dispositive power over 19,345,361 shares, with no shared voting or dispositive power. The filing notes that one client vehicle, iShares Core S&P Small-Cap ETF, has an interest in FMC common stock exceeding five percent of the total outstanding common stock. The schedule is signed on behalf of BlackRock by a Managing Director, supported by a power of attorney.
FMC Corp reports that Pierre R. Brondeau, Chairman, CEO and President, acquired 44 shares of common stock on July 16, 2026. The shares were issued at no cost as dividend equivalent rights tied to vested restricted stock units, bringing his direct holdings to 533,913 shares.
CORDEIRO EDUARDO E reported acquisition or exercise transactions in this Form 4 filing.
FMC Corp director Eduardo E. Cordeiro reported the issuance of 131 shares of common stock on 2026-07-16. These shares were granted at $0.0000 per share pursuant to dividend equivalent rights tied to vested restricted stock units, raising his direct holdings to 41,011 shares.
DAVIDSON CAROL ANTHONY reported acquisition or exercise transactions in this Form 4 filing.
FMC Corp director Carol Anthony Davidson received a grant of 83 shares of Common Stock on 2026-07-16. The shares were issued at no cash cost as dividend equivalent rights tied to vested restricted stock units. Following this award, Davidson directly owns 32,574 FMC shares.
Fortmann Kathy Lynn reported acquisition or exercise transactions in this Form 4 filing.
Kathy Lynn Fortmann, a director of FMC Corp, reported receiving a grant of 101 shares of common stock on July 16, 2026. These shares were issued as dividend equivalent rights tied to vested restricted stock units. After this award, she directly holds 23,653 FMC shares.
FMC Corp director Johnson KLynne reported an acquisition of 184 shares of Common Stock on 2026-07-16. The shares were issued at $0.0000 per share pursuant to dividend equivalent rights tied to vested restricted stock units, increasing direct holdings to 44,535 shares.
FMC Corp director Michael F. Barry reported an acquisition of 11 shares of common stock on July 16, 2026. The shares were issued at no cash cost pursuant to dividend equivalent rights tied to his vested restricted stock units. Following this award, he directly holds 28820.1910 shares.